Pharmaceutical

60 Degrees pauses Phase IIB Covid-19 trial for tafenoquine

The company plans to refile the IND after assessing the feasibility of US FDA-suggested trial modifications.

Sep 19, 2023 - 20:00
60 Degrees pauses Phase IIB Covid-19 trial for tafenoquine
The company plans to refile the IND after assessing the feasibility of US FDA-suggested trial modifications.
Read the original article

Tags:

Previous Article

Otsuka and Astex’s oral Inaqovi wins European approval for AML

Next Article

Pelican and Primordial Genetics merge to form biotech company Primrose Bio

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Amgen sees highest patent filings and grants during July in Q3 2023

Amgen sees highest patent filings and grants during Jul...

Nov 24, 2023

STAT+: Pharmalittle: Regeneron wins a delayed approval; Bristol, J&J likely to face pricing negotiation

STAT+: Pharmalittle: Regeneron wins a delayed approval;...

Aug 21, 2023

STAT+: Amazon strikes partnership with 3M to advance conversational AI in medicine

STAT+: Amazon strikes partnership with 3M to advance co...

Apr 19, 2023